Alteplase


Thông tin thuốc gốc
Chỉ định và Liều dùng
Injection
Clearance of central venous lines
Adult: As 1 mg/mL soln: ≥30 kg: As 1 mg/mL soln: 2 mg instilled into the catheter, may repeat after 2 hr if needed. Max total dose: 4 mg. <30 kg: 110% of the internal lumen volume of the catheter, may repeat after 2 hr if needed. Max total dose: 2 mg.

Intravenous
Acute myocardial infarction
Adult: Accelerated regimen (admin w/in 6 hr of symptom onset): ≥65 kg: 15 mg as bolus, then 50 mg via infusion over 30 min, followed by 35 mg via infusion over 1 hr; <65 kg: 15 mg as bolus, then 0.75 mg/kg (max 50 mg) via infusion over 30 min, followed by 0.5 mg/kg (max 35 mg) via infusion over 1 hr. Max total dose: 100 mg. 3-hr regimen (admin between 6-12 hr after symptom onset): 10 mg as bolus, then 50 mg via infusion over 1 hr, followed by 10 mg via infusion over 30 min until max dose over 3 hr. Max total dose: 100 mg (1.5 mg/kg in patients <65 kg).

Intravenous
Acute massive pulmonary embolism
Adult: Initially, 10 mg as bolus over 1-2 min, followed by 90 mg via infusion over 2 hr. Max total dose: 100 mg (1.5 mg/kg in patients <65 kg).

Intravenous
Acute ischaemic stroke
Adult: 0.9 mg/kg via infusion over 60 min, given w/in 3-4.5 hr after onset of symptoms, w/ 10% of the dose given initially as bolus over the 1st min. Max total dose: 90 mg.
Hepatic Impairment
Intravenous:
Severe: Contraindicated.
Hướng dẫn pha thuốc
IV infusion: Add 50 mL of sterile water for inj to a vial containing 50 mg to obtain a final concentration of 1 mg/mL. It may be further diluted w/ sterile NaCl 0.9% soln for inj to a concentration of approx 0.5 mg/mL. Swirl gently and/or invert slowly until complete dissolution. Inj into occluded catheter: Add 2.2 mL of sterile water for inj to a vial containing 2 mg to provide a concentration of 1 mg/mL.
Tương kỵ
Incompatible w/ bacteriostatic water, Lactated Ringer’s, and glucose 5%. Y-site admin: Incompatible w/ bivalirudin, dobutamine, dopamine, heparin, morphine.
Chống chỉ định
Bleeding disorder (at present or w/in 6 mth), severe stroke, haemorrhagic diathesis, intracranial and subarachnoid haemorrhage, aneurysm, history of CNS damage (i.e. neoplasm, spinal injury), severe uncontrolled HTN, bacterial endocarditis, pericarditis, acute pancreatitis, ulcerative GI disease, oesophageal varices, major surgery or significant trauma in the past 3 mth. Use of rigid catheters. Severe hepatic impairment, including hepatic failure, cirrhosis, portal HTN and active hepatitis.
Thận trọng
Patient w/ mild stroke, thrombocytopenia, haemostatic defect. Patient who recently had surgery, obstetrical delivery, percutaneous biopsy of deep tissues, puncture of non-compressible blood vessels, cardiac massage. Venous thrombosis in the region of catheter, presence of infection in the catheter. Pregnancy and lactation.
Phản ứng phụ
Superficial haematoma or ecchymoses, gingival bleeding, melaena, haematuria, haemoptysis, epistaxis. Rarely, eye and pericardial haemorrhage, rash, urticaria, bronchospasm, angioedema, pyrexia.
Potentially Fatal: Severe spontaneous bleeding (intracranial, retroperitoneal, GI, resp tract, genitourinary), recurrent ischaemia/angina pectoris, heart failure, pulmonary oedema, cardiogenic shock, cardiac arrest and reinfarction, reperfusion arrhythmia, sepsis, cholesterol embolisation.
IV/Parenteral: C
MonitoringParameters
Assess vital signs and ECG prior to, during, and after therapy. Perform neurologic assessments every 15 min during infusion and every 30 min thereafter for the next 6 hr, then hrly until 24 hr of treatment. Monitor BP and heart rate continually for at least 24 hr. Assess catheter function (by attempting to aspirate blood), and bleeding potential through clinical evidence and monitoring of prothrombin time (PT) and aPTT.
Quá liều
Symptoms: Reduction in blood coagulation components (e.g. fibrinogen), severe bleeding. Management: Treat severe bleeding w/ infusion of fresh frozen plasma. Synthetic antifibrinolytics may be beneficial.
Tương tác
Increased risk of haemorrhage w/ coumarin derivatives, oral anticoagulants, platelet aggregation inhibitors, and unfractioned heparin/LMWH. Increased risk of anaphylactoid reaction w/ ACE inhibitors. Concomitant use w/ IV glyceryl trinitrate may result in impaired thrombolysis.
Tác dụng
Description: Alteplase, a recombinant human tissue plasminogen activator (t-PA), activates fibrin-bound plasminogen into plasmin, initiating fibrinolysis and dissolution of thrombus (fibrin clots).
Duration: Up to 1 hr.
Pharmacokinetics:
Metabolism: Metabolised mainly in the liver.
Excretion: Elimination half-life: 4-5 min (initial); approx 40 min (terminal).
Bảo quản
Store below 30°C or between 2-8°C. Protect from light.
Phân loại ATC
B01AD02 - alteplase ; Belongs to the class of enzymes. Used in the treatment of thrombosis.
References
Anon. Alteplase. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/09/2016.

Buckingham R (ed). Alteplase. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/09/2016.

Cathflo Activase – Injection, Powder, Lyophilized for Solution (Genentech, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/09/2016.

Joint Formulary Committee. Alteplase. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/09/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Alteplase. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 01/09/2016.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Alteplase từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in